Radium 223 (Ra-223) was approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) patients with bone-only disease, following demonstration of significant improvement in overall survival (OS). To date, there are no validated prognostic factors useful in predicting outcome of mCRPC patients treated with Ra-223. Our retrospective study aims to evaluate the prognostic role of treatment discontinuation due to adverse events in mCRPC patients treated with Ra-223, and to identify which factors correlate with the toxicity onset.
Methods:
We performed a retrospective analysis of all consecutive mCRPC patients treated with Ra-223 from September 2013 to December 2019 at our institute. Patients were divided in 2 groups according to the reason of Ra-223 therapy discontinuation: toxicity versus other causes. Outcome measures were progression-free survival (PFS) and OS.
Results:
In the overall population (75 patients) median PFS and OS were 5.46 months and 11.15 months respectively. Patients who discontinued treatment due to toxicity had a lower median PFS (3.49 vs 5.89 months, HR: 1.88, 95% CI: 1.14-3.12, p = 0.014) and OS (8.59 vs 14.7 months HR: 3.33, 95% CI: 1.85-6.01, p < 0.001) than patients who discontinued therapy due to other causes. The risk of Ra-223 discontinuation due to toxicity correlates with the number of previous treatments (p = 0.002), previous chemotherapy treatment (p = 0.039), baseline LDH (p = 0.012), Hb (p = 0.021) and platelet-to-lymphocyte ratio (p = 0.024).
Conclusions:
Discontinuation due to toxicity is associated with worse outcomes in mCRPC patients treated with Ra-223. To reduce the risk of developing toxicities that may compromise treatment efficacy, Ra-223 should be used early in mCRPC patients.
SayeghNSwamiUAgarwalN.Recent advances in the management of metastatic prostate cancer. JCO Oncol Pract2022; 18: 45-55.
2.
ParkerCNilssonSHeinrichD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med2013; 369: 213-23.
3.
SaadFGleasonDMMurrayR, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst2002; 94: 1458-1468.
4.
FizaziKCarducciMSmithM, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet2011; 377: 813-822.
5.
HarrisonMRWongTZArmstrongAJ, et al. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res2013; 5: 1-14.
6.
RitterMACleaverJETobiasCA.High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature1977; 266: 653-655.
7.
DeshayesERoumiguieMThibaultC, et al. Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther2017; 11: 2643-2651.
8.
SmithMParkerCSaadF, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2019; 20: 408-419. Erratum in: Lancet Oncol 2019; 20: e559.
9.
FuocoVArgiroffiGMazzagliaS, et al. Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori Epub ahead of print 18 August 2021. DOI: doi-org.bibliopass.unito.it/10.1177/03008916211037732.
10.
SartorOde BonoJChiKN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New Eng J Med2021; 385: 1091–1103.
KuppenMCWestgeestHMvan der DoelenMJ, et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncol2020; 16: 1371-1384.
13.
FosbølMØPetersenPMKjaerAMortensenJ. 223Ra therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicity. J Nucl Med2018; 59: 596-602.
14.
CookGJVenkitaramanRSohaibAS, et al. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging2011; 38: 7-13.
15.
ScherHIHalabiSTannockI, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol2008; 26: 1148-1159.
16.
HeinrichDBekticJBergmanAM, et al. The contemporary use of radium-223 in metastatic castration-resistant prostate cancer. Clin Genitourin Cancer2017: S1558-7673(17)30275-6.
17.
SartorOColemanRENilssonS, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol2017; 28:1090-1097.
18.
BaldariSBoniGBortolusR, et al. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. Crit Rev Oncol Hematol2017; 113: 43-51.
19.
UedaYMatsubaraNTabataKI, et al. Prostate-specific antigen flare phenomenon induced by abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer2017; 15: 320-325.
20.
PetersNGaffneyJConnollyE, et al. Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience. J Clin Oncol2020; 38: 228-228.
21.
SaadFKeizmanDO’SullivanJM, et al. Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP). J Clin Oncol2016; 34: 5082-5082.
22.
Al-EzziEM, et al. Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium223. J Clin Oncol2020; 38: 225–225.
23.
SartorOVogelzangNJSweeneyC, et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first u.s. experience from an expanded access program. Oncologist2018; 23: 193-202.
24.
FrantellizziVFarcomeniAFollacchioGA, et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride. Ann Nucl Med2018; 32: 142-148.
25.
BaucknehtMRebuzziSESignoriA, et al. The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with radium-223: A proof of concept study. Cancers (Basel)2020; 12: 3213.
26.
VidalMDelgadoAMartinezC, et al. Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223. Int Braz J Urol2020; 46: 599-611.
27.
YamamotoYOkudaYKanakiT, et al. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. Int J Clin Oncol2021; 26: 192-198.
28.
LeisserANejabatMHartenbachM, et al. Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment. Oncotarget2018; 9: 16197-16204.
29.
SolowayMSHardemanSWHickeyD, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer1988; 61: 195-202.
30.
YongCOnukwughaEMullinsCD.Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol2014; 26: 274-283.
31.
LangePHVessellaRL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev1998-1999; 17: 331-336.
32.
RoodmanGD.Mechanisms of bone metastasis. N Engl J Med2004; 350: 1655-1664
33.
VignaniFBertagliaVButtiglieroC, et al. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev2016; 44: 61-73.
34.
ParikhSMurrayLKenningL, et al. Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer. Clin Oncol (R Coll Radiol)2018; 30: 548-555.
35.
WongWWAndersonEMMohammadiH, et al. Factors associated with survival following radium-223 treatment for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer2017; 15: e969-e975.
36.
HalabiSSmallEJKantoffPW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol2003; 21: 1232-1237.
37.
DaiDHanSLiL, et al. Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis. Am J Transl Res2018; 10: 3877-3886.
38.
LiFXiangHPangZ, et al. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis. Cancer Med2020; 9: 7341-7351.
39.
CostaRPBordonaroSCappuccioF, et al. Hematologic toxicity of radium-223 in elderly patients with metastatic castration resistant prostate cancer: a real-life experience. Prostate Int2019; 7: 25-29.
40.
WangJZhouXHeY, et al. Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. Medicine (Baltimore)2018; 97: e12504.
41.
SharmaDBrummel-ZiedinsKEBouchardBA, et al. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol2014; 229: 1005-1015.
42.
UsluAUKüçükAŞahinA, et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis2015; 18: 731-735
43.
ColottaFAllavenaPSicaA, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis2009; 30: 1073-1081.
44.
GillessenSAttardGBeerTM, et al. Management of patients with advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol2020; 77: 508-547.
45.
SartorOColemanRMorrisMJ, et al. 2530 Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA. Eur J Cancer2015; 51: S484-S485.
46.
SartorOHoskinPColemanRE, et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate2016; 76: 905-916.
47.
ButtiglieroCTucciMBertagliaV, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev2015; 41: 884-892.
48.
TucciMZichiCButtiglieroC, et al. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Onco Targets Ther2018; 11: 7353-7368.
49.
PisanoCTucciMDi StefanoRF, et al. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. Crit Rev Oncol Hematol2021; 157: 103185.
50.
CursanoM. C.IulianiM.CasadeiC., et al. (2020). Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. Critical Rev Oncol Hematol2020; 146: 102864.
51.
MorrisMJCoreyEGuiseTA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nature reviews. Urology. 2019; 16: 745–756.
52.
van der DoelenMJIsaacsson VelhoPSlootbeekP, et al. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. Eur J Cancer2020; 136: 16–24.
53.
PezaroCOmlinALorenteD, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol2014; 65: 270-273.
54.
ParkerCHeidenreichANilssonS, et al. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis2018; 21: 37-47.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
